Casgevy, Lyfgenia Medicare Add-On Payments In Sickle Cell Are Not Conditioned On Outcomes-Based Contracting

 
• By Cathy Kelly

The CMS supplemental reimbursement for the gene therapies is higher than usual for new technologies, but is similar to the formula used for antibiotics.

Hospitals Still Face High Medical Costs Associated With the Gene Therapies Treatment. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies